<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52729">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02419742</url>
  </required_header>
  <id_info>
    <org_study_id>ML28714</org_study_id>
    <nct_id>NCT02419742</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen</brief_title>
  <official_title>An Indian Multicentric Open Label Prospective Phase IV Study to Evaluate Safety &amp; Efficacy of Trastuzumab in HER2 Positive, and High Risk Node Negative Breast Cancer as Part of a Treatment Regimen Consisting of Doxorubicin, Cyclophosphamide, With Either Docetaxel or Paclitaxel (AC --&gt;TH) or Docetaxel and Carboplatin (TCH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This is a prospective, phase IV, multi-center, single arm, open-label, interventional study
      in patients with Human Epidermal growth factor Receptor 2 (HER2)-positive node positive or
      High risk node negative breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing clinically significant changes in laboratory tests for cardiac function</measure>
    <time_frame>Within 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing Adverse Events</measure>
    <time_frame>Within 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>Within 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Within 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">109</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>AC-TH regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anthracycline based therapy (AC-TH) consists of Doxorubicin and cyclophosphamide followed by docetaxel or paclitaxel. Trastuzumab is started concurrently with docetaxel or paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TCH regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-anthracycline based therapy (TCH) consists of Docetaxel and carboplatin will be given along with adjuvant therapy of Trastuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin Dose=Area Under Curve [AUC], 6 mg*mL/min X (Glomerular Filtration Rate [GFR] + 25) administered I.V. over 1 hour every 3 weeks for 6 cycles.</description>
    <arm_group_label>TCH regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 600 mg/m^2 administered as a 5 to 60 minute I.V. bolus injection every 3 weeks for 4 cycles.</description>
    <arm_group_label>AC-TH regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel 100 mg/m^2</intervention_name>
    <description>Docetaxel 100 mg/m^2 (at investigator's discretion or Paclitaxel) will be administered as a 1-hour I.V. infusion every 3 weeks for four cycles, beginning on Day 1 of Cycle 5.</description>
    <arm_group_label>AC-TH regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel 75 mg/m^2</intervention_name>
    <description>Docetaxel 75 mg/m^2 as a 60-minute I.V. bolus injection every 3 weeks.</description>
    <arm_group_label>TCH regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 60 mg/m^2 administered as a 5 to 15 minute intravenous (I.V.) bolus injection every 3 weeks for 4 cycles.</description>
    <arm_group_label>AC-TH regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 175 mg/m^2 (at investigator's discretion or docetaxel 100 mg/m^2) will be administered as a 1-hour I.V. infusion every 3 weeks for four cycles, beginning on Day 1 of Cycle 5.</description>
    <arm_group_label>AC-TH regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab (Anthracycline based therapy (AC-TH))</intervention_name>
    <description>Trastuzumab loading dose 4 mg/kg body weight administered as a 90 minute intravenous infusion followed by a weekly dose 2 mg/kg body weight administered as a 30 minute infusion or 8 mg/kg (Loading dose) followed by 6 mg/kg every 3 weeks.</description>
    <arm_group_label>AC-TH regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab (Non-anthracycline based therapy (TCH))</intervention_name>
    <description>Trastuzumab loading dose 4 mg/kg body weight administered as a 90 minute intravenous infusion followed by a weekly dose 2 mg/kg body weight administered as a 30 minute infusion or 8 mg/kg (Loading dose) followed by 6 mg/kg every 3 weeks.</description>
    <arm_group_label>TCH regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed early invasive HER2 positive, node positive or high risk
             node negative breast cancer with no evidence of residual, locally recurrent or
             metastatic disease and defined as clinical stage I to IIIA that is eligible for
             adjuvant treatment with Trastuzumab.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

          -  HER2 over-expression/amplification defined as either IHC3+, or IHC2+ and Fluorescence
             in situ Hybridization (FISH) positive as determined in a central laboratory.

          -  At time of starting Trastuzumab therapy, Left ventricular ejection fraction (LVEF)
             measured by echocardiography.

          -  Screening left ventricular ejection fraction (LVEF) =/&gt; 55%.

          -  Adequate bone marrow, renal, and hepatic function.

          -  Agreement to use an adequate, non-hormonal means of contraception by women of
             childbearing potential.

        Exclusion Criteria:

          -  Any contraindication to Trastuzumab.

          -  Previous adjuvant breast cancer treatment with an approved or investigational
             anti-HER2 agent.

          -  History of other malignancy, except for curatively treated carcinoma in situ of the
             cervix or basal cell carcinoma and patients with other curatively treated
             malignancies who have been disease-free for at least 5 years.

          -  Past history of ductal carcinoma in situ and/or lobular carcinoma that has been
             treated with any systemic therapy or with radiation therapy to the ipsilateral breast
             where the invasive cancer subsequently develops.

          -  Locally advanced (stage IIIB and IIIC) and Metastatic disease (stage IV).

          -  Clinically relevant cardiovascular disorder or disease.

          -  Uncontrolled hypertension, or history of hypertensive crisis or hypertensive
             encephalopathy.

          -  History of severe allergic or immunological reactions, e.g. difficult to control
             asthma.

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anil Kukreja, MD</last_name>
    <role>Study Director</role>
    <affiliation>Roche Products (India) Pvt. Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML28714 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110 085</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560017</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Delhi</city>
        <zip>110092</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Trichy</city>
        <zip>620008</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Vellore</city>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 1, 2016</lastchanged_date>
  <firstreceived_date>March 23, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
